JPY1,394.50
0.29% yesterday
Tokyo, May 23, 08:15 am CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Stock price

JPY1,393.00
+25.00 1.83% 1M
-179.00 11.39% 6M
-141.50 9.22% YTD
-168.00 10.76% 1Y
-600.00 30.11% 3Y
-353.00 20.22% 5Y
-424.50 23.36% 10Y
Tokyo, Closing price Fri, May 23 2025
+2.50 0.18%
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Key metrics

Market capitalization JPY2.50t
Enterprise Value JPY3.12t
P/E (TTM) P/E ratio 49.15
EV/FCF (TTM) EV/FCF 22.72
EV/Sales (TTM) EV/Sales 1.63
P/S ratio (TTM) P/S ratio 1.31
P/B ratio (TTM) P/B ratio 1.65
Dividend yield 5.60%
Last dividend (FY26) JPY78.00
Revenue growth (TTM) Revenue growth -3.35%
Revenue (TTM) Revenue JPY1.91t
EBIT (operating result TTM) EBIT JPY40.25b
Free Cash Flow (TTM) Free Cash Flow JPY137.18b
Cash position JPY218.31b
EPS (TTM) EPS JPY28.34
P/E forward 17.24
P/S forward 1.29
EV/Sales forward 1.60
Show more

Is Astellas Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Astellas Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Astellas Pharma forecast:

5x Buy
38%
7x Hold
54%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Astellas Pharma forecast:

Buy
38%
Hold
54%
Sell
8%

Financial data from Astellas Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,912,323 1,912,323
3% 3%
100%
- Direct Costs 349,206 349,206
3% 3%
18%
1,563,117 1,563,117
3% 3%
82%
- Selling and Administrative Expenses 843,032 843,032
10% 10%
44%
- Research and Development Expense 327,651 327,651
9% 9%
17%
177,011 177,011
27% 27%
9%
- Depreciation and Amortization 136,762 136,762
27% 27%
7%
EBIT (Operating Income) EBIT 40,249 40,249
70% 70%
2%
Net Profit 50,747 50,747
1% 1%
3%

In millions JPY.

Don't miss a Thing! We will send you all news about Astellas Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Naoki Okamura
Employees 14,754
Founded 1923
Website www.astellas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today